im not sure how old this article is, possibly just before...

im not sure how old this article is, possibly just before dendreon received fda approval for provenge. Easy to understand and see the potential prr has in the future IMO. :)

ASX:PRR: ?New FDA guidance may lighten Prima?s regulatory load?
by admin

PRR: ?PRIMA Biomed?s path to market may have been boosted by the release last week of new draft guidance from the US Food and Drug Administration on the approval of therapeutic cancer vaccines.?

?Deutsche Bank, in a research note on Dendreon last week, said the FDA appeared to be moving towards allowing approval of therapeutic cancer vaccines on the basis of overall survival in clinical trials, rather than the more common mark of progression-free survival.?

?The report said this implied the FDA would likely support Provenge approval even though it did not delay tumour progression but rather exhibited a survival benefit, according to US media reports.?

?Prima Biomed director Martin Rogers said that, while he hadn?t had a chance to review the new guidance in detail, it looked as though it might benefit Prima. ?Deutsche Bank says it?s good for Dendreon and anything that?s good for Dendreon is good for us,??

- BioTechnologyNews.net